Table 2. Prevalence rates at enrolment and incidence rates during 12 months of follow up of stavudine associated toxicities in 253 Malawian adults.

Toxicity	Prevalence Rate*		Incidence Rate
	PR (%)	95%-CI	IR (/100 py)	95%-CI
Peripheral neuropathy	21.3	16.5–26.9	19.8	14.3–26.6
Lipodystrophy	14.7	2.4–8.1	11.4	7.5–16.3
Pancreatitis	0	0–1.5	0	0.0–0.2
Diabetes mellitus	0.8	0–2.8	0.4	0.0–1.4
High lactate syndrome †	0	0–1.4	2.1	0.7–4.9
Increased TC (>200 mg/dL)	11.9	8.1–16.4	9.9	7.9–13.3
Increased TG (>110 mg/dL)	5.5	3.1–9.1	13.9	9.2–16.7
Any toxicity ¶	22.9	17.8–28.6	26.7	20.1–34.8

^*Prevalence at enrolment i.e. after one year of stavudine containing ART.

^¶One or more of peripheral neuropathy, lipodystrophy, pancreatitis, hyperlactate syndrome, diabetes mellitus.

^†severe hyperlactatemia, symptomatic hyperlactatemia and lactic acidosis, as defined in methods paragraph.

IR, incidence rate; PR, prevalence rate; CI, confidence interval; py, person-years; TC, total cholesterol serum level; TG, triglyceride serum level.